Results 291 to 300 of about 2,000,070 (348)
Advanced Functional Materials, EarlyView.Two pyridinium‐based ionic liquid templated hybrid manganese halides, (C4Py)2[MnCl4] and (C4Py)2[MnBr4], display similar bulk structures but show significantly different photoluminescence behaviors due to the bromine heavy‐atom effect. Their stable local Mn environments remain intact even in the molten state, allowing applications such as luminescence ...
Biswajit Bhattacharyya +22 more
wiley +1 more source
Multiplex Modular Nanorobotic Systems with Catalytic Activity under Magnetic Navigation
Advanced Functional Materials, EarlyView.We present modular nanorobots composed of a magnetic propulsion module and different extension modules carrying functional activities, assembled via DNA base pairing. The system integrates propulsion, optical tracking, enzymatic catalysis, and cell docking in a programmable manner.
Voichita Mihali +7 more
wiley +1 more source
Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study. [PDF]
J Clin MedCoppola A +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Thrombosis and Haemostasis, 1997
Despite the introduction of recombinant preparations of factor VIII and recombinant factor VII and VIIa, patients with other forms of hemophilia, especially hemophilia B, have remained at increased risk for blood borne viruses because of a lack of clinically utilizable preparations of recombinant factor IX.
G C, White, A, Beebe, B, Nielsen
openaire +2 more sources
Despite the introduction of recombinant preparations of factor VIII and recombinant factor VII and VIIa, patients with other forms of hemophilia, especially hemophilia B, have remained at increased risk for blood borne viruses because of a lack of clinically utilizable preparations of recombinant factor IX.
G C, White, A, Beebe, B, Nielsen
openaire +2 more sources
Blood Coagulation & Fibrinolysis, 1992
Within the past 20 years or so, factor IX has been at the centre of particularly intensive studies of its physiology, pathology and biochemistry as well as its molecular genetics and biology. With the complete nucleotide sequence of its human gene determined in 1985 and the molecular defects of over 600 abnormal human factor IX genes analysed to date ...
K, Kurachi +3 more
openaire +3 more sources
Within the past 20 years or so, factor IX has been at the centre of particularly intensive studies of its physiology, pathology and biochemistry as well as its molecular genetics and biology. With the complete nucleotide sequence of its human gene determined in 1985 and the molecular defects of over 600 abnormal human factor IX genes analysed to date ...
K, Kurachi +3 more
openaire +3 more sources
Heterogeneity of factor IX in therapeutic factor IX concentrates
Thrombosis Research, 1978Abstract Rabbit antibody to human factor IX was used to investigate the factor IX antigenic content and electrophoretic mobility of commercial products as well as experimental “activated products”. Rocket immunoelectrophoresis of all concentrates showed a 1.2–3 fold increased antigenic content/unit factor IX clotting activity when compared to plasma.
D, Menache, D L, Aronson
openaire +2 more sources
Immune Reactive Factor IX in Acquired Factor IX Deficiency
Thrombosis and Haemostasis, 1972SummaryFactor IX-antibody-neutralizing material has been estimated in plasmas of patients with acquired factor IX deficiency. In patients with liver cirrhosis and patients who had been treated with L-Asparaginase the plasma neutralized an amount of antibody expected from the biological activity. In patients treated with phenprocoumon and in one patient
openaire +2 more sources